TrialMultiple sclerosis (Houndmills, Basingstoke, England)2023

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.

Shannon Kolind et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.